Skip to main content
Atencion Primaria logoLink to Atencion Primaria
. 2008 Nov 18;38(8):456–460. [Article in Spanish] doi: 10.1157/13094803

Evolución en el consumo de antidepresivos durante los años 2002 a 2004

Evolution in consumption of anti-depressants during the years 2002 to 2004

Catalina Serna Arnáiz a,, Leonardo Galván Santiago b, Eduardo Gascó Eguíluz c, Plácido Santafé Soler d, Elisabeth Martín Gracia e, Teresa Vila Parrot f
PMCID: PMC7668707  PMID: 17194371

Abstract

Objective

To analyse the use of antidepressants from 2002 to 2004 and the length of treatment.

Design

Cross-sectional, descriptive study of antidepressant drugs prescribed through the National Health System during 2002-2004.

Setting

Lleida Health Region, Spain.

Participants

A total of 54 890 patients received an antidepressant drug between 2002 and 2004.

Measurements

Age, sex, medicine, prescription period, centre.

Results

The prevalence of antidepressant treatment was: 8.4% in 2002 (368 976 inhabitants); 8.6% in 2003 (376 638 inhabitants); and 8.7% in 2004 (388 148 inhabitants). The increase in antidepressant treatment in 2004 over 2002 was 9.4%. Prevalence among men was 5.4% and women, 12.7%. The distribution according to antidepressant classes was: selective serotonin reuptake inhibitors, 73.7%; tricyclic antidepressants, 26.2%; heterocyclic antidepressants, 10%, and monoamine oxidase inhibitors, 0.1%.The duration of treatment was 1 to 3 months (43%), 4 to 12 months (22.7%), 13 to 24 months (14.4%), and over 24 months (19.9%).

Conclusions

A steady increase in the use of antidepressants is being observed, predominantly new drugs. Regarding the length of treatment, a high proportion of patients are treated for under 4 months, which does not follow recent recommendations in the scientific literature for treatment of depression. This is a major element of inefficiency in the health system.

Key words: Depression, Epidemiology, Prevalence, Antidepressants

Bibliografía

  • 1.Murray CJ, López AD, Mathers CD, Stein C. The global burden of disease 2000 project: aims, methods and data sources. Geneva: World Health Organization (BPE Discussion Paper n.o 36); 2001.
  • 2.Alonso J., Angermeyer M.C., Bernert S., Bruffaerts R., Brugha T.S., Bryson H. Prevalence of mental disorders in Europe results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;(420):21–27. doi: 10.1111/j.1600-0047.2004.00327.x. [DOI] [PubMed] [Google Scholar]
  • 3.Alonso M.P., De Abajo F.J., Martínez J.J., Montero D., Martín-Serrano G., Madurga M. Evolución del consumo de antidepresivos en España. Impacto de los inhibidores selectivos de la recaptación de serotonina. Med Clin (Barc) 1997;108:161–166. [PubMed] [Google Scholar]
  • 4.Nomenclator Digitalis. Madrid: INSALUD; 2000.
  • 5.Garcia Iñesta A. Instituto Nacional de la Salud, editor Estudios de utilización de medicamentos. INSALUD; Madrid: 1992. Estudios de utilización de medicamentos en España y análisis de la situación farmacoterapéutica. p. 15-48. [Google Scholar]
  • 6.Ley 14/1986 de 25 de abril, Ley General de Sanidad. BOE núm. 112 de 24/4/86.
  • 7.Sartor F., Walckiers D. Estimate of disease prevalence using drug consumption data. Am J Epidemiol. 1995;141:782–787. doi: 10.1093/oxfordjournals.aje.a117502. [DOI] [PubMed] [Google Scholar]
  • 8.Ortiz Lobo A., Lozano Serrano C. El incremento en la prescripción de antidepresivos. Aten Primaria. 2005;35:152–155. doi: 10.1157/13071941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Travé Rodríguez A.L., Reneses Sacristán A. Manejo de los fármacos en el tratamiento de la depression. Información Terapéutica. 2002;1:1–8. [Google Scholar]
  • 10.Díaz Madero A., López Ferreras A., Ruiz-Clavijo Díez M.T., Vargas Aragón M.L. Evolución del consumo de antidepresivos en el área de Zamora desde 1996 a1999. Aten Primaria. 2001;28:333–339. doi: 10.1016/S0212-6567(01)70385-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Rodríguez D. Situació actual del tractament de la depressió. Butlletí d’Informació Terapéutica. 2004;16:49–54. [Google Scholar]
  • 12.Alonso J., Angermeyer M.C., Bernert S., Bruffaerts R., Brugha T.S., Bryson H. Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;(420):55–64. doi: 10.1111/j.1600-0047.2004.00331.x. [DOI] [PubMed] [Google Scholar]
  • 13.Tomás Azanar C., Moreno Aznar L.A., Germán Bes C., Alcalá Nalváiz T., Andrés Esteban E. Dependencia y necesidades de cuidados no cubiertas de las personas mayores de una zona de salud de Zaragoza. Rev Esp Salud Pública. 2002;76:215–226. [PubMed] [Google Scholar]
  • 14.Berardi D., Menchetti M., De Ronchi D., Rucci P., Leggieri G., Ferrar G. Late-life depression in primary care: a nationwide Italian epidemiological survey. J Am Geriatr Soc. 2002;50:77–83. doi: 10.1046/j.1532-5415.2002.50011.x. [DOI] [PubMed] [Google Scholar]
  • 15.Kendrick T. Prescribing antidepressants in general practice. Watchful waiting for minor depression, full dose treatment for major depression. BMJ. 1996;313:829–830. doi: 10.1136/bmj.313.7061.829. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES